Dupilumab‐Induced Psoriasis in an Adolescent With Severe Atopic Dermatitis: Successful Management With Abrocitinib

Psoriasiform eruptions have been described in patients treated with dupilumab. This case report describes an adolescent with severe atopic dermatitis who developed a widespread psoriasiform dermatitis 8 months after starting dupilumab. His therapy was switched to abrocitinib resulting in near-complete resolution of the psoriatic lesions with good atopic dermatitis control. This case adds to the limited pediatric literature on dupilumab-induced psoriasis and highlights abrocitinib as an effective therapeutic alternative capable of addressing both conditions concurrently.